RxDoctor Payments Data

Michael Barden, MD

Family Medicine · Searcy, ARNPI 1427018043

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 85 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$335
  • AbbVie$245
  • Amgen$171
  • AstraZeneca$75
  • Novo Nordisk$68
  • Medtronic$67
  • plus $447 from 14 others

What the payments were for

  • Food & beverage$1,39399%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,408 in reported general payments places this provider in the 65th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$112,385
Medicare patients
526
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide208$226,233
Trelegy ElliptaFluticasone/Umeclidin/Vilanter118$91,771
EliquisApixaban138$87,100
JardianceEmpagliflozin96$75,490
MounjaroTirzepatide59$68,093
XareltoRivaroxaban95$62,556
TrulicityDulaglutide40$39,509
FarxigaDapagliflozin Propanediol48$37,749
JanuviaSitagliptin Phosphate36$30,842
ZenpepLipase/Protease/Amylase11$30,762
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog69$23,499
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$22,688
LexaproEscitalopram Oxalate12$15,558
Lantus SolostarInsulin Glargine,hum.Rec.Anlog97$14,162
MyrbetriqMirabegron26$11,391

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$68$226,233208 claims
GSKTrelegy Ellipta, Anoro Ellipta, Incruse Ellipta, Breo Ellipta$335$134,230204 claims
Lilly USA, LLCMounjaro, Trulicity$28$107,60199 claims
PfizerEliquis, Prempro$25$91,292156 claims
Boehringer IngelheimJardiance, Spiriva Respimat$36$85,562115 claims
Johnson & JohnsonXarelto$65$62,55695 claims
AstraZenecaFarxiga, Symbicort, Breztri Aerosphere$75$52,90687 claims
MerckJanuvia, Janumet, Belsomra$15$43,96760 claims
AbbVieLexapro, Synthroid$245$19,53097 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →